Pacira BioSciences, Inc. (PCRX)
| Market Cap | 1.00B -11.5% |
| Revenue (ttm) | 746.16M +5.7% |
| Net Income | 14.64M |
| EPS | 0.35 |
| Shares Out | 39.86M |
| PE Ratio | 71.67 |
| Forward PE | 7.92 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 469,793 |
| Open | 25.04 |
| Previous Close | 25.01 |
| Day's Range | 24.66 - 25.66 |
| 52-Week Range | 18.80 - 27.66 |
| Beta | 0.25 |
| Analysts | Buy |
| Price Target | 30.00 (+19.02%) |
| Est. Earnings | Nov 5, 2026 |
About PCRX
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled dos... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for PCRX stock is "Buy." The 12-month stock price target is $30.0, which is an increase of 19.02% from the latest price.
News
Pacira initiated with an Outperform at Oppenheimer
Oppenheimer initiated coverage of Pacira (PCRX) with an Outperform rating and $32 price target The firm believes Exparel is entering a “stronger commercial phase.” Expanding separate reimbursement, ou...
Pacira initiated with a Market Perform at Leerink amid ‘formulary inertia’
As previously reported, Leerink analyst Daniel Clark initiated coverage of Pacira (PCRX) with a Market Perform rating and $28 price target The setup for Exparel has improved with the enactment…
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of pat...
Pacira initiated with a Market Perform at Leerink
Leerink initiated coverage of Pacira (PCRX) with a Market Perform rating and $28 price target
Pacira reinstated with a Buy at Truist
Truist analyst Anish Nikhanj reinstated coverage of Pacira (PCRX) with a Buy rating and $30 price target The company is positioned for “reliable and steadily” growing cash flows from Exparel,…
Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases
— A single locally administered intra-articular injection of PCRX-201 into the knee was well tolerated in patients with moderate-to-severe knee osteoarthritis —
Pacira price target raised to $25 from $24 at RBC Capital
RBC Capital analyst Douglas Miehm raised the firm’s price target on Pacira (PCRX) to $25 from $24 and keeps a Sector Perform rating on the shares.
Pacira BioSciences Earnings Call Transcript: Q2 2026
Q2 2026 saw 6% revenue growth to $192.4M, strong adjusted EBITDA, and expanded payer coverage for EXPAREL and ZILRETTA. The iovera° divestiture sharpened focus on biopharma innovation, while pipeline catalysts and commercial momentum position the company for continued growth.
Pacira BioSciences Earnings release: Q2 2026
Pacira BioSciences released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Pacira BioSciences Slides: Q2 2026
Pacira BioSciences has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
Pacira BioSciences Quarterly report: Q2 2026
Pacira BioSciences has published its Q2 2026 quarterly earnings report on August 4, 2026.
Pacira BioSciences Reports Second Quarter 2026 Financial Results
-- Continued execution of 5x30 strategy marked by solid revenue growth, durable cashflows, advancing pipeline, and high-caliber commercial partnerships -- -- Delivered second quarter total revenue of ...
Pacira transitions PCRX-201 to a U.S.-based manufacturing process
Pacira (PCRX) announced that it has successfully transitioned PCRX-201, its investigational locally administered gene therapy for osteoarthritis of the knee, to a U.S.-based scalable commercial manufa...
Pacira BioSciences Advances PCRX-201 Development Program with Successful Transition to Scalable Commercial Manufacturing Process
— First patient enrolled in Part B of Phase 2 ASCEND study enabled by availability of drug product from new manufacturing process — — Topline data from Part A of Phase 2 ASCEND study remains on track ...
Pacira to Report Second Quarter 2026 Financial Results on Tuesday August 4, 2026
BRISBANE, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the liv...
Pacira announces UnitedHealth provides separate reimbursement for Exparel
Pacira (PCRX) announced that UnitedHealthcare (UNH) now provides separate reimbursement for Exparel across outpatient settings, including hospital outpatient departments and ambulatory surgery centers...
Pacira BioSciences Announces UnitedHealthcare Now Provides Separate Reimbursement for EXPAREL®
-- Expands Patient Access to Non-Opioid Postsurgical Pain Management Across Outpatient Settings -- BRISBANE, Calif., July 01, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the in...
Pacira Zimmer to divest iovera degrees to Biomet for $70M upfront
Pacira (PCRX) announced the divestiture of iovera degrees to Zimmer Biomet (ZBH). The iovera degrees system is a FDA-cleared, drug-free medical device that relieves pain via cryoneurolysis-a process w...
Pacira BioSciences Announces Agreement to Divest its iovera° Business to Zimmer Biomet
-- Pacira to receive up to $140 million with $70 million upfront and up to an additional $70 million in potential future revenue-based milestone payments -- -- Two companies will collaborate on advanc...
20 growth stocks priced as value stocks
A broad screen of U.S. stocks yields a list of companies trading at low valuations to expected earnings, with high projected revenue growth rates through 2028. The list of 20 stocks includes eight fin...
Pacira BioSciences Announces Stockholders Have Elected All Three of the Company's Director Nominees at Annual Meeting
BRISBANE, Calif., June 9, 2026 /PRNewswire/ -- Pacira BioSciences, Inc. (Nasdaq: PCRX) (the "Company" or "Pacira"), the industry leader in its commitment to deliver innovative, non-opioid pain therapi...
Pacira BioSciences Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Management outlined a robust growth strategy centered on expanding non-opioid pain management, leveraging strong Q1 results, and advancing a diversified pipeline. Key catalysts include upcoming data readouts, expanded market access, and a strengthened patent estate supporting long-term exclusivity.
Pacira BioSciences Reminds Stockholders to Vote the BLUE Proxy Card "FOR" the Election of the Company's Highly Qualified Nominees Ahead of its Annual Meeting
Election of Even a Single DOMA Nominee Would Risk Compromising Pacira's Strong Forward Momentum Leading Independent Experts ISS, Glass Lewis and Egan-Jones Agree that DOMA Representation Is Not Warran...
Pacira BioSciences Proxy statement: Proxy filing
Pacira BioSciences filed a proxy statement on June 4, 2026, providing details for shareholder voting and corporate governance matters.
Pacira BioSciences Transcript: Jefferies Global Healthcare Conference 2026
The company is executing a 5x30 growth strategy, expanding payer access and partnerships, and expects double-digit growth for EXPAREL. Key pipeline readouts, including PCRX-201 for knee OA, are anticipated by year-end, while robust IP and manufacturing complexity protect market position.